RNA binding protein RBM3 increases β-catenin signaling to increase stem cell characteristics in colorectal cancer cells
Anand Venugopal
Department of Molecular and Integrative Physiology, The University of Kansas Medical Center, Kansas City, Kansas
Search for more papers by this authorDharmalingam Subramaniam
Department of Molecular and Integrative Physiology, The University of Kansas Medical Center, Kansas City, Kansas
Search for more papers by this authorJulia Balmaceda
Department of Molecular and Integrative Physiology, The University of Kansas Medical Center, Kansas City, Kansas
Search for more papers by this authorBadal Roy
Department of Molecular and Integrative Physiology, The University of Kansas Medical Center, Kansas City, Kansas
Search for more papers by this authorDan A. Dixon
Department of Cancer Biology, The University of Kansas Medical Center, Kansas City, Kansas
Search for more papers by this authorShahid Umar
Department of Molecular and Integrative Physiology, The University of Kansas Medical Center, Kansas City, Kansas
Search for more papers by this authorScott J. Weir
Department of Pharmacology, Toxicology and Therapeutics, The University of Kansas Medical Center, Kansas City, Kansas
Search for more papers by this authorCorresponding Author
Shrikant Anant
Department of Molecular and Integrative Physiology, The University of Kansas Medical Center, Kansas City, Kansas
Correspondence to: The University of Kansas Medical Center, 3901 Rainbow Boulevard, 4019 Wahl Hall East, MS 3040, Kansas City, KS 66160, USA.
Search for more papers by this authorAnand Venugopal
Department of Molecular and Integrative Physiology, The University of Kansas Medical Center, Kansas City, Kansas
Search for more papers by this authorDharmalingam Subramaniam
Department of Molecular and Integrative Physiology, The University of Kansas Medical Center, Kansas City, Kansas
Search for more papers by this authorJulia Balmaceda
Department of Molecular and Integrative Physiology, The University of Kansas Medical Center, Kansas City, Kansas
Search for more papers by this authorBadal Roy
Department of Molecular and Integrative Physiology, The University of Kansas Medical Center, Kansas City, Kansas
Search for more papers by this authorDan A. Dixon
Department of Cancer Biology, The University of Kansas Medical Center, Kansas City, Kansas
Search for more papers by this authorShahid Umar
Department of Molecular and Integrative Physiology, The University of Kansas Medical Center, Kansas City, Kansas
Search for more papers by this authorScott J. Weir
Department of Pharmacology, Toxicology and Therapeutics, The University of Kansas Medical Center, Kansas City, Kansas
Search for more papers by this authorCorresponding Author
Shrikant Anant
Department of Molecular and Integrative Physiology, The University of Kansas Medical Center, Kansas City, Kansas
Correspondence to: The University of Kansas Medical Center, 3901 Rainbow Boulevard, 4019 Wahl Hall East, MS 3040, Kansas City, KS 66160, USA.
Search for more papers by this authorAbstract
Colorectal cancer (CRC) is the second leading cause of cancer deaths in the United States. It arises from loss of intestinal epithelial homeostasis and hyperproliferation of the crypt epithelium. In order to further understand the pathogenesis of CRC it is important to further understand the factors regulating intestinal epithelial proliferation and more specifically, regulation of the intestinal epithelial stem cell compartment. Here, we investigated the role of the RNA binding protein RBM3 in stem cell homeostasis in colorectal cancers. Using a doxycycline (Dox) inducible RBM3 overexpressing cell lines HCT 116 and DLD-1, we measured changes in side population (SP) cells that have high xenobiotic efflux capacity and increased capacity for self-renewal. In both cell lines, RBM3 induction showed significant increases in the percentage of side population cells. Additionally, we observed increases in spheroid formation and in cells expressing DCLK1, LGR5 and CD44Hi. As the Wnt/β-catenin signaling pathway is important for both physiologic and cancer stem cells, we next investigated the effects of RBM3 overexpression on β-catenin activity. RBM3 overexpression increased levels of nuclear β-catenin as well as TCF/LEF transcriptional activity. In addition, there was inactivation of GSK3β leading to decreased β-catenin phosphorylation. Pharmacologic inhibition of GSK3β using (2′Z,3′E)-6-Bromoindirubin-3′-oxime (BIO) also recapitulates the RBM3 induced β-catenin activity. In conclusion, we see that RNA binding protein RBM3 induces stemness in colorectal cancer cells through a mechanism involving suppression of GSK3β activity thereby enhancing β-catenin signaling. © 2015 Wiley Periodicals, Inc.
Supporting Information
Additional supporting information may be found in the online version of this article at the publisher's web-site.
Filename | Description |
---|---|
mc22404-sup-0001-SuppFig-S1.tif24.1 MB |
Figure S1. Induction of GFP does not affect inhibition of proliferation by paclitaxel or doxorubicin. HCT 116 Tet-GFP cells were treated with varying concentrations of paclitaxel or doxorubicin and increasing concentration of Doxycyclin (0–500 ng/mL) to induce GFP. There was no difference in proliferation rate in either cells line due to the presence of doxycyclin. |
mc22404-sup-0002-SuppFig-S2.tif24.1 MB |
Figure S2. RBM3 overexpression shows modest increase in total β-catenin and mRNA levels of its transcriptional targets. (A) Western blot of DLD-1 and HCT 116 GFP or RBM3 inducible cells with indicated doses and durations of Dox induction. (B) Real time PCR analysis of β-catenin transcriptional targets c-Myc, CD44 and LGR5 and western blot for c-Myc protein expression following 72 h of 500 ng/mL Dox induction. Bar graphs show SEM. P values obtained from Student's t-test. |
mc22404-sup-0003-SuppFig-S3.tif24.1 MB |
Figure S3. siCTNNB1 shows knockdown of β-catenin levels. Western blot analysis of total β-catenin protein following transfection of siCTNNB1. |
mc22404-sup-0004-SuppFig-S4.tif24.1 MB |
Figure S4. RBM3 mediated β-catenin increases are replicated by GSK3β inhibition. (A) Western blot of HCT 116 inducible GFP or RBM3 cells with indicated treatment of Dox or BIO for 72 h. (B) Western blot of cytoplasmic and nuclear fractions of HCT116 Tet-RBM3 cells treated with indicated concentrations of Dox or BIO for 72 h. (C) Western blot of c-Myc expression in HCT116 Tet-GFP and Tet-RBM3 cells following indicated treatment with Dox or BIO for 72 h. |
mc22404-sup-0005-SuppFig-S5.tif10.3 MB |
Figure S5. Primer sequences used for gene expression analyses. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1 Derry JM, Kerns JA, Francke U. RBM3, a novel human gene in Xp11.23 with a putative RNA-binding domain. Hum Mol Genet 1995; 4: 2307–2311.
- 2 Danno S, Nishiyama H, Higashitsuji H, et al. Increased transcript level of RBM3, a member of the glycine-rich RNA-binding protein family, in human cells in response to cold stress. Biochem Biophys Res Commun 1997; 236: 804–807.
- 3 Kita H, Carmichael J, Swartz J, et al. Modulation of polyglutamine-induced cell death by genes identified by expression profiling. Hum Mol Genet 2002; 11: 2279–2287.
- 4 Ferry AL, Vanderklish PW, Dupont-Versteegden EE. Enhanced survival of skeletal muscle myoblasts in response to overexpression of cold shock protein RBM3. Am J Physiol Cell Physiol 2011; 301: C392–C402.
- 5 Chip S, Zelmer A, Ogunshola OO, et al. The RNA-binding protein RBM3 is involved in hypothermia induced neuroprotection. Neurobiol Dis 2011; 43: 388–396.
- 6 Wellmann S, Truss M, Bruder E, et al. The RNA-binding protein RBM3 is required for cell proliferation and protects against serum deprivation-induced cell death. Pediatr Res 2009; 67: 35–41.
- 7 Sureban SM, Ramalingam S, Natarajan G, et al. Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe. Oncogene 2008; 27: 4544–4556.
- 8 Grupp K, Wilking J, Prien K, et al. High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions. Eur J Cancer 2014; 50: 852–861.
- 9 Shaikhibrahim Z, Lindstrot A, Ochsenfahrt J, Fuchs K, Wernert N. Epigenetics-related genes in prostate cancer: Expression profile in prostate cancer tissues, androgen-sensitive and -insensitive cell lines. Int J Mol Med 2013; 31: 21–25.
- 10 Zhang HT, Zhang ZW, Xue JH, et al. Differential expression of the RNA-binding motif protein 3 in human astrocytoma. Chin Med J (Engl) 2013; 126: 1948–1952.
- 11 Zeng Y, Kulkarni P, Inoue T, Getzenberg RH. Down-regulating cold shock protein genes impairs cancer cell survival and enhances chemosensitivity. J Cell Biochem 2009; 107: 179–188.
- 12 Jogi A, Brennan DJ, Ryden L, et al. Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer. Mod Pathol 2009; 22: 1564–1574.
- 13 Jonsson L, Bergman J, Nodin B, et al. Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: An analysis of 215 cases from the malmo diet and cancer study. J Transl Med 2011; 9: 114–122.
- 14 Ehlen A, Brennan DJ, Nodin B, et al. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer. J Transl Med 2010; 8: 78–89.
- 15American Cancer Society ( 2013); Cancer Facts & Figures 2013: (American Cancer Society, Atlanta, GA).
- 16 Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759–767.
- 17 Fodde R, Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol 2007; 19: 150–158.
- 18 Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer 2007; 7: 79–94.
- 19 Welsh GI, Proud CG. Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B. Biochem J 1993; 294: 625–629.
- 20 Brabletz S, Schmalhofer O, Brabletz T. Gastrointestinal stem cells in development and cancer. J Pathol 2009; 217: 307–317.
- 21 Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755–768.
- 22 Okano H, Kawahara H, Toriya M, Nakao K, Shibata S, Imai T. Function of RNA-binding protein Musashi-1 in stem cells. Exp Cell Res 2005; 306: 349–356.
- 23 King CE, Wang L, Winograd R, et al. LIN28B fosters colon cancer migration, invasion and transformation through let-7-dependent and -independent mechanisms. Oncogene 2011; 30: 4185–4193.
- 24 Yang J, Zhang W, Evans PM, Chen X, He X, Liu C. Adenomatous polyposis coli (APC) differentially regulates beta-catenin phosphorylation and ubiquitination in colon cancer cells. J Biol Chem 2006; 281: 17751–17757.
- 25 Mathew G, Timm EA, Jr., Sotomayor P, et al. ABCG2-mediated DyeCycle Violet efflux defined side population in benign and malignant prostate. Cell Cycle 2009; 8: 1053–1061.
- 26 Subramaniam D, May R, Sureban SM, et al. Diphenyl difluoroketone: A curcumin derivative with potent in vivo anticancer activity. Cancer Res 2008; 68: 1962–1969.
- 27 Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996; 183: 1797–1806.
- 28 Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 2004; 101: 14228–14233.
- 29 Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5: 219–234.
- 30 Kanwar SS, Yu Y, Nautiyal J, Patel BB, Majumdar AP. The Wnt/beta-catenin pathway regulates growth and maintenance of colonospheres. Mol Cancer 2010; 9: 212–224.
- 31 Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111–115.
- 32 Dontu G, Abdallah WM, Foley JM, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003; 17: 1253–1270.
- 33 Barker N, van Es JH, Kuipers J, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007; 449: 1003–1007.
- 34 May R, Riehl TE, Hunt C, Sureban SM, Anant S, Houchen CW. Identification of a novel putative gastrointestinal stem cell and adenoma stem cell marker, doublecortin and CaM kinase-like-1, following radiation injury and in adenomatous polyposis coli/multiple intestinal neoplasia mice. Stem Cells 2008; 26: 630–637.
- 35 Barker N, Ridgway RA, van Es JH, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009; 457: 608–611.
- 36 Nakanishi Y, Seno H, Fukuoka A, et al. Dclk1 distinguishes between tumor and normal stem cells in the intestine. Nat Genet 2013; 45: 98–103.
- 37 Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704–715.
- 38 Zeng Y, Wodzenski D, Gao D, et al. Stress-response protein RBM3 Attenuates the stem-like properties of prostate cancer cells by interfering with CD44 variant splicing. Cancer Res 2013; 73: 4123–4133.
- 39 Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer 2008; 8: 387–398.
- 40 Wielenga VJ, Smits R, Korinek V, et al. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol 1999; 154: 515–523.
- 41 Chikazawa N, Tanaka H, Tasaka T, et al. Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells. Anticancer Res 2010; 30: 2041–2048.
- 42 He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998; 281: 1509–1512.
- 43 Mottet D, Dumont V, Deccache Y, et al. Regulation of hypoxia-inducible factor-1alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta pathway in HepG2 cells. J Biol Chem 2003; 278: 31277–31285.
- 44 Wellmann S, Buhrer C, Moderegger E, et al. Oxygen-regulated expression of the RNA-binding proteins RBM3 and CIRP by a HIF-1-independent mechanism. J Cell Sci 2004; 117: 1785–1794.
- 45 van Weeren PC, de Bruyn KM, de Vries-Smits AM, van Lint J, Burgering BM. Essential role for protein kinase B (PKB) in insulin-induced glycogen synthase kinase 3 inactivation. Characterization of dominant-negative mutant of PKB. J Biol Chem 1998; 273: 13150–13156.
- 46 Knall C, Young S, Nick JA, Buhl AM, Worthen GS, Johnson GL. Interleukin-8 regulation of the Ras/Raf/mitogen-activated protein kinase pathway in human neutrophils. J Biol Chem 1996; 271: 2832–2838.
- 47 Meijer L, Skaltsounis AL, Magiatis P, et al. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol 2003; 10: 1255–1266.
- 48 Liu KP, Luo F, Xie SM, et al. Glycogen Synthase Kinase 3beta Inhibitor (2'Z,3'E)-6-Bromo-indirubin- 3'-Oxime Enhances Drug Resistance to 5-Fluorouracil Chemotherapy in Colon Cancer Cells. Chin J Cancer Res 2012; 24: 116–123.
- 49 Behnan J, Isakson P, Joel M, et al. Recruited brain tumor-derived mesenchymal stem cells contribute to brain tumor progression. Stem Cells 2014; 32: 1110–1123.
- 50 Kudo-Saito C. Cancer-associated mesenchymal stem cells aggravate tumor progression. Front Cell Dev Biol 2015; 3: 23–28.
- 51 Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008; 8: 726–736.
- 52 Yang X, Hou J, Han Z, et al. One cell, multiple roles: Contribution of mesenchymal stem cells to tumor development in tumor microenvironment. Cell Biosci 2013; 3: 5–14.
- 53 Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 1997; 40: S13–S19.
- 54 Galluzzi L, Vitale I, Michels J, et al. Systems biology of cisplatin resistance: Past, present and future. Cell Death Dis 2014; 5: e1257–e1274.
- 55 Yoshida T, Hashimura M, Mastumoto T, et al. Transcriptional upregulation of HIF-1alpha by NF-kappaB/p65 and its associations with beta-catenin/p300 complexes in endometrial carcinoma cells. Lab Invest. 2013; 93: 1184–1193.
- 56 Mazumdar J, O'Brien WT, Johnson RS, et al. O2 regulates stem cells through Wnt/beta-catenin signalling. Nat Cell Biol 2010; 12: 1007–1013.
- 57 Kaidi A, Williams AC, Paraskeva C. Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol 2007; 9: 210–217.